Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash from Investing Activities (2019 - 2025)

Harmony Biosciences Holdings' Cash from Investing Activities history spans 7 years, with the latest figure at -$17.6 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 145.35% year-over-year to -$17.6 million; the TTM value through Dec 2025 reached -$39.6 million, up 41.25%, while the annual FY2025 figure was -$39.6 million, 41.25% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$17.6 million at Harmony Biosciences Holdings, down from -$4.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $2.4 million in Q1 2025 and bottomed at -$100.0 million in Q1 2021.
  • The 5-year median for Cash from Investing Activities is -$7.8 million (2023), against an average of -$20.8 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 34787.1% in 2022 before it skyrocketed 191.64% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$93000.0 in 2021, then crashed by 50324.73% to -$46.9 million in 2022, then rose by 23.09% to -$36.1 million in 2023, then skyrocketed by 80.07% to -$7.2 million in 2024, then crashed by 145.35% to -$17.6 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Cash from Investing Activities are -$17.6 million (Q4 2025), -$4.8 million (Q3 2025), and -$19.6 million (Q2 2025).